The Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway is a chain of interactions between proteins in a cell.
The JAK-STAT signaling pathway transmits information from extracellular chemical signals to the nucleus resulting in DNA transcription and expression of genes involved in immunity, proliferation, differentiation, apoptosis and oncogenesis. This pathway plays a prominent role in mediating signal transduction for many cytokines.
There are three key parts of JAK-STAT signaling pathway: Janus kinases (JAKs), Signal Transducer and Activator of Transcription proteins (STATs), and receptors (which bind the chemical signals). In mammals, the JAK/STAT pathway is the principal signaling mechanism for a wide array of cytokines and growth factors.
Following the binding of cytokines to their cognate receptor, STATs are activated by members of the JAK family of tyrosine kinases. Once activated, they dimerize and translocate to the nucleus and modulate the expression of target genes.
In addition to the activation of STATs, JAKs mediate the recruitment of other molecules such as the MAP kinases, PI3 kinase etc. These molecules process downstream signals via the Ras-Raf-MAP kinase and PI3 kinase pathways which results in the activation of additional transcription factors.
Dysregulation of JAK-STAT signaling is associated with various immune disorders. Accumulating evidence has discovered that STAT3 SNPs is associated with Crohn’s disease, psoriasis and ankylosing spondylitis, STAT4 SNPs is associated with rheumatoid arthritis, Crohn’s disease, systemic lupus erythematosus and Sjogren’s syndrome, and STAT6 SNPs is associated with asthma.
Additionally, given the researches implicating JAK-STAT in autoimmune disease and malignancy, it is not surprising that this pathway has become an attractive target for pharmaceuticals. Ruxolitinib, a JAK1 and JAK2 inhibitor with efficacy for the treatment of polycythemia vera and myelofibrosis, was the first FDA approved JAK inhibitor, or Jakinib.
|CSH1||CSH1 Antibody||CSH1 Protein||CSH1 cDNA||CSH1 ELISA Kit|
|CTF1||CTF1 Antibody||CTF1 Protein||CTF1 cDNA||CTF1 ELISA Kit|
|EGF||EGF Antibody||EGF Protein||EGF cDNA||EGF ELISA Kit|
|EGFR||EGFR Antibody||EGFR Protein||EGFR cDNA||EGFR ELISA Kit|
|EP300||EP300 Antibody||EP300 Protein||EP300 cDNA||EP300 ELISA Kit|
|EPO||EPO Antibody||EPO Protein||EPO cDNA||EPO ELISA Kit|
|EPOR||EPOR Antibody||EPOR Protein||EPOR cDNA||EPOR ELISA Kit|
|FHL1||FHL1 Antibody||FHL1 Protein||FHL1 cDNA||FHL1 ELISA Kit|
|GFAP||GFAP Antibody||GFAP Protein||GFAP cDNA||GFAP ELISA Kit|
|GH1||GH1 Antibody||GH1 Protein||GH1 cDNA||GH1 ELISA Kit|
|GH2||GH2 Antibody||GH2 Protein||GH2 cDNA||GH2 ELISA Kit|
|GHR||GHR Antibody||GHR Protein||GHR cDNA||GHR ELISA Kit|
|GRB2||GRB2 Antibody||GRB2 Protein||GRB2 cDNA||GRB2 ELISA Kit|
|HRAS||HRAS Antibody||HRAS Protein||HRAS cDNA||HRAS ELISA Kit|
|IFNA1||IFNA1 Antibody||IFNA1 Protein||IFNA1 cDNA||IFNA1 ELISA Kit|
|IFNA10||IFNA10 Antibody||IFNA10 Protein||IFNA10 cDNA||IFNA10 ELISA Kit|
|IFNA13||IFNA13 Antibody||IFNA13 Protein||IFNA13 cDNA||IFNA13 ELISA Kit|
|IFNA14||IFNA14 Antibody||IFNA14 Protein||IFNA14 cDNA||IFNA14 ELISA Kit|
|IFNA16||IFNA16 Antibody||IFNA16 Protein||IFNA16 cDNA||IFNA16 ELISA Kit|
|IFNA17||IFNA17 Antibody||IFNA17 Protein||IFNA17 cDNA||IFNA17 ELISA Kit|